No transactions reported by Spero Therapeutics (SPRO) director William Ho.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Spero Therapeutics Inc.'s recent Form 3 filing identifies William Ho as a new director, reporting zero transactions. The filing, accepted by the SEC on November 10, 2026, also includes a director power-of-attorney exhibit. This indicates that while Mr. Ho has joined the board, he has not yet engaged in any beneficial ownership activities of company securities.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.